Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Almirall, S.A. (BME:ALM), a global biopharmaceutical company focused on skin health, announced today the U.S. commercial launch of Klisyri®...
Almirall, S.A. (BME:ALM), a global biopharmaceutical company focused on skin health, announced today that the New England Journal of Medicine (NEJM)...
Almirall, S.A. (BME:ALM), a global biopharmaceutical company focused on skin health, announced today that Klisyri® (tirbanibulin) has been approved...
Almirall LLC today announced that the FDA approved an important update to the Seysara® label stating that P. acnes strains displayed a low propensity ...
- Almirall, ein führendes spanisches biopharmazeutisches Unternehmen, das 2007 erstmals an der Börse notiert wurde, ist in den wichtigsten Index der...
Almirall, S.A. (Madrid: ALM), a global pharmaceutical company focused on skin health, has been selected by the IBEX Technical Advisory Committee...
Almirall, S.A. (ALM), a leading global pharmaceutical company focused on medical dermatology, and 23andMe, the leading consumer genetics and research ...
Almirall, S.A. (ALM) and WuXi Biologics ("WuXi Bio") (2269.HK) have today announced the signing of an agreement. Through this collaboration Almirall...
Almirall, S.A. (ALM) has announced today the execution of an option agreement to acquire Bioniz Therapeutics, Inc. a clinical stage biopharmaceutical ...
Almirall LLC today announced the publication of long-term safety data from a 40 week, Phase 3 open-label extension study of Seysara® in patients 9...
Almirall LLC announced today the FDA approval of the expanded indication for Aczone® 7.5% Gel to include patients aged 9-11. Aczone® 7.5% Gel is a...
Almirall, S.A. (ALM) announced today the opening of a new call for proposals for their AlmirallShare open innovation platform, looking to find...
Almirall announced today their partnership with the American Acne and Rosacea Society to highlight the global health burden of acne during National...
Almirall was recognized this week with the Distinguished Corporate Leadership award by the American Skin Association (ASA). Ron Menezes, President...
Almirall, S.A. (ALM) and Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and...
Almirall S.A. (ALM) announced that it has entered into a definitive agreement with Celling Biosciences, based in Austin (Texas), to divest ThermiGen...
Almirall, S.A. (ALM), today announced that an abstract reporting the results from two Phase III studies of KX2-391 Ointment in the treatment of...
Almirall LLC announces the launch of Seysara™ (sarecycline), a novel tetracycline-derived oral antibiotic developed specifically for the treatment of ...
Almirall, LLC, formerly Aqua Pharmaceuticals, a U.S. leader in skin health medical solutions, used the start of the Fall Clinical Dermatology...
Almirall, S.A. (ALM) announced today the finalization of their acquisition of products from Allergan's Medical Dermatology unit in the United States: ...
New affiliate to support forthcoming Canadian product launches TORONTO, Sept. 5, 2013 /CNW/ - Almirall, the international pharmaceutical company...
Dados positivos do estudo MOVE 2 (MObility ImproVEments with Spasticity in Multiple Sclerosis),apresentado no congresso ECTRIMS, consubstanciam a...
Die positiven Daten aus der Studie MObility ImproVEments with Spasticity in Multiple Sclerosis (MOVE) 2, die auf dem ECTRIMS-Kongress vorgelegt...
Dati positivi dallo studio MObility ImproVEments with Spasticity in Multiple Sclerosis (MOVE) 2, presentato in occasione del Congresso ECTRIMS, a...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.